Abstract：Objective To investigate the expression of IFN-λ1 in respiratory epithelial cells of children with respiratory syncytial virus (RSV) infection and its relationship with RSV load. Methods The nasopharyngeal swabs were collected from the children who were hospitalized with respiratory tract infection from June 2015 to June 2016. A direct immunofluorescence assay was used to detect the antigens of seven common respiratory viruses (including RSV) in the nasopharyngeal swabs. A total of 120 children who were only RSV positive were selected as the RSV infection group. A total of 50 children who had negative results in the detection of all viral antigens were selected as the healthy control group. Fluorescence quantitative real-time PCR was used to determine the RSV load and the expression of IFN-λ1 mRNA in the nasopharyngeal swabs of children in the two groups. Results The expression of IFN-λ1 in the RSV infection group was significantly higher than that in the healthy control group (P < 0.05). The expression of IFN-λ1 was positively correlated with RSV load (r=0.56, P < 0.05). Conclusions RSV can induce the expression of IFN-λ1 in respiratory epithelial cells, suggesting that IFN-λ1 may play an important role in anti-RSV infection.
TAO Mei-Ting,XIE Ya-Ping,LIU Shu-Ping et al. Expression of interferon-λ1 in respiratory epithelial cells of children with RSV infection and its relationship with RSV load[J]. CJCP, 2017, 19(6): 677-681.
Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus[J]. Rev Med Virol, 2004, 14(3):149-168.
[2]
Hasegawa K, Jartti T, Mansbach JM, et al. Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis:multicenter cohort studies in the United States and Finland[J]. J Infect Dis, 2015, 211(10):1550-1559.
[3]
Zickert A, Oke V, Parodis I, et al. Interferon (IFN)-λ is a potential mediator in lupus nephritis[J]. Lupus Sci Med, 2016, 3(1):e000170.
[4]
Selvaggi C, Pierangeli A, Fabiani M, et al. Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis[J]. J Infect, 2014, 68(5):467-477.
[5]
Eslam M, George J. Targeting IFN-λ:therapeutic implications[J]. Expert Opin Ther Targets, 2016, 20(12):1425-1432.
[6]
Bullens DM, Decraene A, Dilissen E, et al. Type III IFN-λ mRNA expression in sputum of adult and school-aged asthmatics[J]. Clin Exp Allergy, 2008, 38(9):1459-1467.
[7]
Lin M, Yu HP. Dexamethasone decreases IL-29 expression in house dust mite-stimulated human bronchial epithelial cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(6):823-827.
Iversen MB, Paludan SR. Mechanisms of type III interferon expression[J]. J Interferon Cytokine Res, 2010, 30(8):573-578.
[11]
Pagliaccetti NE, Robek MD. Interferon-λ in the immune response to hepatitis B virus and hepatitis C virus[J]. J Interferon Cytokine Res, 2010, 30(8):585-590.
[12]
Ilyushina NA, Donnelly RP. In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate[J]. Antiviral Res, 2014, 111:112-120.
[13]
Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface[J]. Immunol Rev, 2013, 255(1):25-39.
[14]
Dellgren C, Gad HH, Hamming OJ, et al. Human interferon-λ3 is a potent member of the type III interferon family[J]. Genes Immun, 2009, 10(2):125-131.
[15]
Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-λ production in asthma exacerbations[J]. Nat Med, 2006, 12(9):1023-1026.
